Aravive, a clinical-stage oncology company, has added Dr. Peter Ho, Dr. John Hohneker and Sigurd Kirk to its board of directors. “Their experience in biopharmaceutical and healthcare senior executive leadership positions will be valuable to the company as we continue to advance our AVB-500 clinical development program to treat life-threatening cancers,” said Aravive chairman Fred Eshelman, Pharm.D., in a statement.